A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema baseline features

Retina

Volumn 28, Issue 7, 2008, Pages 919-930

  Ip, Michael S ^a   Bressler, Susan B ^b   Antoszyk, Andrew N ^c   Flaxel, Christina J ^d   Kim, Judy E ^e   Friedman, Scott M ^f   Qin, Haijing ^g  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Charlotte Eye Ear Nose and Throat Associates   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f Central Florida Retina Institute   (United States)

^g JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Baseline characteristics; Clinical trial; Diabetic macular edema; Diabetic Retinopathy Clinical Research Network; Intravitreal injection; Laser photocoagulation; Study design; Triamcinolone

Indexed keywords

TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE DURATION; ETHNICITY; FEMALE; GLYCEMIC CONTROL; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RACE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 50249139773     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31818144a7     Document Type: Article

References (16)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-1474.
2. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101: 1061-1070.
3. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
4. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (United Kingdom Prospective Diabetes Study 33). Lancet 1998;352:837-853.
6. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Homan RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49:1761-1769.
7. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
8. Flynn HW Jr, Scott I. Intravitreal triamcinolone acetonide for macular edema associated with diabetic retinopathy and venus occlusive disease: it's time for clinical trials. Arch Ophthalmol 2005;123:258-259.
9. Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125:469-480.
10. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98:823-833.
11. Gardner TW, Sander B, Larson ML, et al. An extension of the early treatment diabetic retinopathy study (EDTRS) system for grading of diabetic macular edema in the astemizole retinopathy trial. Curr Eye Res 2006;31:535-547.
12. The PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113:2221-2230.
13. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98:741-756.
14. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosolated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871.
15. Bressler NM, Edwards AR, Antoszyk AN, et al. Retinal thickness on stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol 2008;145:894-901.
16. Chew EY, FL F, Csaky KG, Murphy RP. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy. The early treatment diabetic retinopathy follow-up study. Ophthalmology 2003;110:1683-1689.